# Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus

> **NCT06057077** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ministry of Health, Saudi Arabia** · enrollment: 120 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Semaglutide weekly injection

## Key facts

- **NCT ID:** NCT06057077
- **Lead sponsor:** Ministry of Health, Saudi Arabia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057077, "Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06057077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*